Navigation Links
Unigene's Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
Date:11/30/2011

rally-restricted kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain.  In a previous randomized, placebo-controlled Phase II study, CR845 demonstrated evidence of analgesic efficacy when administered as a single intravenous dose to women following laparoscopic hysterectomy.  In addition to decreases in reported pain levels, patients receiving CR845 required substantially lower amounts of post-operative opioids (narcotics) and showed a significant reduction in the incidence of post-operative nausea and vomiting. A multicenter double-blind, randomized, placebo-controlled 200-patient Phase II trial is ongoing to evaluate the efficacy and safety of intravenous CR845 when administered both pre- and post-operatively in women undergoing laparoscopic hysterectomy. Analysis of this trial is expected in 1Q'12.  To date, more than 150 human subjects have been exposed to CR845 with no cases of the dysphoria or hallucinations that have been reported with centrally-acting kappa opioids.  For more information visit: www.caratherapeutics.com.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expert
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
5. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
6. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
7. Nventa Develops Proprietary Vaccine Adjuvant
8. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
11. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , Mar. 27, 2015 Research and ... the addition of the "European Laboratory Information ... System), by Type (Clinical Pathology Laboratory Information System, ... 2019" report to their offering. ... to grow at a CAGR of 7.6% from ...
(Date:3/31/2015)... N.J. , March 31, 2015  PAION, ... today announced the initiation of a U.S. Phase ... for procedural sedation in patients undergoing colonoscopy. ... faster onset of sedation and greater procedural success ... profile and patients experienced rapid recovery from sedation ...
(Date:3/30/2015)... , 31 mars 2015  Une équipe de scientifiques ... atomique d,un récepteur de surface cellulaire qui ... de thromboses. Contre toute attente, cette recherche ... caractéristiques structurelles qui remettent en cause les ... les récepteurs couplés aux protéines G (RCPG) ...
Breaking Medicine Technology:European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 2European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 3PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 2PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 3PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 4De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 2De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 3
... ,, BETHESDA, Md. , June 30 ... an innovator in biotechnology for therapy in diabetes, ... and regulatory consulting services to food, supplement, biotechnology ... subsidiary, Biospherics Incorporated, has signed a license agreement ...
... 30 Xoft, the leading provider of FDA-cleared ... Center of Hoag Memorial Hospital Presbyterian in Newport ... Brachytherapy, eBx™ System to support the launch of its ... progressive, comprehensive approach to breast cancer treatment. The first ...
Cached Medicine Technology:Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 2Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 3Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 4Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 5Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 2Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 3Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 4
(Date:3/31/2015)... (PRWEB) March 31, 2015 Horizon Blue ... today that its efforts to combat health insurance fraud ... a combination of monies recovered and losses avoided -- ... total since Horizon BCBSNJ created its fraud fighting, Special ... BCBSNJ’s anti-fraud efforts have saved members $261 million. ...
(Date:3/31/2015)... An individual’s meniscus (cushion in the knee) ... leg providing stability, load bearing and preservation of the ... Day meeting of the American Orthopaedic Society for Sports ... the potential for biologic healing following a meniscus tear. ... of meniscus tears when a root repair is performed ...
(Date:3/31/2015)... 2015 Burns Engineering announces 3-Day Quick Ship ... the Food & Beverage, Pharmaceutical and Biotech markets. These field ... compliant and are now available as part of Burns’ Quick ... The S01 and S03 with 1/8” and 1/4” ... connections used in process lines 1/4” and larger. Sensors ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By ... (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), ... and studies the major market drivers, restraints, opportunities ... the Rest of the world (RoW). , ... reach $3.58 billion by 2019 from $2.4 billion ...
(Date:3/31/2015)... March 31, 2015 DentalXChange, ... specializes in providing online solutions to connect ... it has achieved full accreditation for the ... Accreditation Program (HNAP) from the Electronic Healthcare ... HNAP accreditation runs in two-year increments and ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Saves Members, Health System a Record $45.4 Million through Anti-fraud Efforts 2Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- Toddlers ... finding that researchers say may provide a clue to the ... is largely an involuntary process that helps keep the eyes ... are closed, you are temporarily blinded. And throughout a typical ...
... infrastructure, inefficient distribution channels and disruptive black markets must ... with the growing problem of malaria, according to a ... Systems and Management . Historically, malaria is humanity,s ... some regions it remains the biggest infectious threat in ...
... , MONDAY, Dec. 12 (HealthDay News) -- Acupuncture may ... according to a new study. Cancer drugs called ... nerves, especially in the calves and feet, resulting in ... is no effective treatment for the condition, called chemotherapy ...
... Reporter , MONDAY, Dec. 12 (HealthDay News) -- When she was ... Madeline Mann was the world,s smallest surviving baby. At the ... world,s tiniest infant, weighing in at 0.57 pounds. She was one ... the neonatal intensive care unit at Loyola University Medical Center in ...
... Reinberg HealthDay Reporter , MONDAY, Dec. 12 ... colon, breast, prostate and cervical cancer even though guidelines ... finds. As the population of the United States ... will be a continuing battle, experts say. "In an ...
... Patients who receive a blood ... to treat leukemia and other blood diseases are more likely ... disease, a condition caused by the donor cells attacking the ... a donor,s bone marrow, rather than from blood stem cells ...
Cached Medicine News:Health News:Blink Patterns May Be a Window Into Autistic Mind 2Health News:Blink Patterns May Be a Window Into Autistic Mind 3Health News:A logistics approach to malaria in Africa 2Health News:Acupuncture Might Ease Chemotherapy Pain 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Are Too Many Older People Screened for Cancer? 2Health News:Are Too Many Older People Screened for Cancer? 3Health News:Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Elmed BC 50 M/M is an all purpose bipolar coagulator with a macro and micro mode. In the micro mode, the unit is ideally suitable for wet-field coagulation in ophthalmology, neurosurgery and other mi...
...
...
Medicine Products: